Pfizer Gets Up to $1.5 Billion from Blackstone to Fund Obesity Drug
Reuters reports Blackstone will provide Pfizer up to $1.5 billion through 2028 to help develop its experimental once-monthly obesity drug, the company said.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Reuters reports that Pfizer announced on Wednesday an agreement under which Blackstone will provide as much as $1.5 billion through 2028. The money is meant to support work on Pfizer's experimental obesity treatment, which is taken once a month.
The arrangement shifts part of the cost of bringing the drug forward to an outside investor.
why it matters
For a large drugmaker, outside funding eases the cash burden of developing one of its most closely watched pipeline assets. Investors often read such deals as a sign of confidence in a program.
market impact
Pfizer: outside funding eases the cost burden of developing the obesity drug
tags
instruments
on polymarket
sources
- Pfizer secures up to $1.5 billion from Blackstone for obesity drug development — Reuters, 11 November 2026 at 21:38 UTC
- Pfizer secures up to $1.5 billion from Blackstone for obesity drug development — Reuters, 11 November 2026 at 22:07 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗